医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting

2013年05月02日 AM12:40
このエントリーをはてなブックマークに追加


 

SAN DIEGO

The following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego, CA:

  • Androgen deprivation therapy by a gonadotropin releasing hormone antagonist, degarelix, lowers the risk of cardiovascular events or death when compared to luteinising hormone-releasing agonists (Abstract 781)

    Date: Monday, May 6, 2013; 8:00-10:00 AM
    Session/Type: Prostate Cancer: Advanced (II); Moderated Poster
    Location: San Diego Convention Center, Room 7
    Authors: Peter Albertsen; Bertrand Tombal; Thomas Wiegel; Egbert van der Meulen; Bo-Eric Persson; Tine Kold Olesen; Joshua Beckman

  • Analysis of disease control-related outcomes from six comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists (Abstract 716)

    Date: Sunday, May 5, 2013; 3:30-5:30 PM
    Session/Type: Prostate Cancer: Advanced (I); Podium Presentation
    Location: San Diego Convention Center, Room 1
    Authors: Neal Shore; Kurt Miller; Bertrand Tombal; E. David Crawford; Cathrina Karup; Egbert van der Meulen; Bo-Eric Persson

Per AUA media embargo policy, coverage of research being presented is prohibited before the date and time of presentation.

About Ferring

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring has its own operating subsidiaries in 50 countries and markets its products in more than 90 countries. To learn more about Ferring or its products, please visit www.ferring.com.

© 2013 Ferring B.V.

FIRMAGON® is a registered trademark of Ferring B.V.

CONTACT

Tonic Life Communications
Molly Wilson, 215-928-2357
molly.wilson@toniclc.com
or
Ferring
Pharmaceuticals
Patrick Gorman, +41 (0) 58 301 00 53
patrick.gorman@ferring.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Cerveau Technologies, Inc. Signs Research Agreement with Kobe City Hospital Organisation, Japan
  • Exactech Earns Research Award at International Computer-Assisted Surgery Conference for ExactechGPS® Knee Application
  • 火山噴火で家屋の破壊と住民の避難が続く中、ハワイ・コミュニティ財団が支援基金を創設
  • Octapharma宣布Nuwiq®产品新增剂量规格在欧洲获准,提高了血友病A患者的给药灵活性
  • PHCホールディングス株式会社:薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始